PT-141
PT-141 is the research name for bremelanotide, which is FDA-approved as Vyleesi for low sexual desire in premenopausal women. Research-grade PT-141 is not the approved product.
What it is
A melanocortin receptor agonist that acts in the brain to affect sexual desire.
What the evidence shows
In people
Phase 3 trials (RECONNECT) supported approval for hypoactive sexual desire disorder in premenopausal women.
In animals and labs
Mechanism work in animals preceded human trials.
Legal status
Approved as Vyleesi for one indication. Not approved for men or for other uses.
Dosing
Only the approved product has a defined dose
The approved product has a dose on its FDA label for one specific use. That dose does not apply to research-grade versions, which can differ in strength and purity. Talk to a prescriber about the approved product.
- Vyleesi · Low sexual desire in premenopausal womenOfficial label on DailyMed ↗
Known risks
- Nausea, flushing, and headache
- Temporary rise in blood pressure
- Darkening of skin or gums with repeated use